Analysis of D-Dimer Levels Based on Histopathological Grading of Breast Cancer

Yessi Devita; Reza Aditya Digambiro; Dewi Hastuty

doi:10.36452/jkdoktmeditek.v31i6.3974

Authors

Yessi Devita Departemen Patologi Anatomi , Fakultas Kedokteran, Universitas Imelda, Medan, Indonesia
Reza Aditya Digambiro Departemen Patologi Anatomi , Fakultas Kedokteran, Universitas Trisakti, Jakarta, Indonesia
Dewi Hastuty Fakultas kedokteran, Universitas Trisakti, Jakarta, Indonesia.

DOI:

https://doi.org/10.36452/jkdoktmeditek.v31i6.3974

Keywords:

breast cancer, D-dimer, histopathological grade, hypercoagulability, prognostic biomarker

Abstract

Background: Breast cancer is the most common malignancy among women worldwide. Systemic activation of coagulation, reflected by elevated D-dimer levels, has been associated with advanced stage, metastasis, and poor prognosis in breast cancer. However, it remains unclear whether D-dimer also correlates with histopathological grade as an indicator of intrinsic tumor aggressiveness, particularly among patients with invasive breast cancer in Indonesia. Objective: To evaluate the association between plasma D-dimer levels and histopathological grading of invasive breast cancer. Methods: This cross-sectional study included 180 untreated female patients with primary invasive breast cancer, comprising 60 cases each of Grade I, Grade II, and Grade III tumors. Plasma D-dimer levels were measured using a latex-enhanced immunoturbidimetric assay, and histological grading was determined according to the Nottingham system. Data were analyzed using the Kruskal–Wallis test, ANOVA on log-transformed values, post-hoc tests, and ANCOVA with adjustment for age, body mass index (BMI), clinical stage, C-reactive protein (CRP), lymphovascular invasion, and molecular subtype. Receiver operating characteristic (ROC) analysis was performed to distinguish Grade III from lower grades. Results: Median D-dimer levels increased progressively from Grade I (501.7 ng/mL) to Grade II (831.0 ng/mL) and Grade III (1312.9 ng/mL), with a statistically significant overall difference (p < 0.001). ROC analysis for identifying Grade III yielded an AUC of 0.960 with an optimal cut-off of 965.5 ng/mL FEU (sensitivity 91.7%, specificity 90.0%). Conclusion: Plasma D-dimer levels are significantly associated with histopathological grade in invasive breast cancer, independent of potential confounders. These findings suggest that D-dimer testing may help identify patients with high-grade tumors at an early stage, thereby refining risk stratification, informing more intensive treatment planning, and raising vigilance for thromboembolic complications, particularly in resource-limited settings..

ctice.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 May [cited 2025 Aug 12];71(3):209–49. Available from: https://doi.org/10.3322/caac.21660

van Dooijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. Virchows Arch [Internet]. 2022 Jan [cited 2025 Jul 28];480:33–43. Available from: https://doi.org/10.1007/s00428-021-03141-2

Wang Y, Acs B, Robertson S, Liu B, Solorzano L, Wählby C, et al. Improved breast cancer histological grading using deep learning. Ann Oncol [Internet]. 2022 Jan 1 [cited 2025 Sep 2];33(1):89–98. Available from: https://doi.org/10.1016/j.annonc.2021.10.018

Trimaille A, Thachil J, Marchandot B, Curtiaud A, Leonard-Lorant I, Carmona A, et al. D-dimers level as a possible marker of extravascular fibrinolysis in COVID-19 patients. J Clin Med [Internet]. 2021 Jan 1 [cited 2025 Jul 19];10(1):200. Available from: https://doi.org/10.3390/jcm10010200

Steven N, Aditama R, Alifia A, Hermawati E, Bachtiar E, Rahmita M, et al. Development of a dimer-based screening system that targets PhoR in Mycobacterium tuberculosis. Indones J Biotechnol [Internet]. 2024 Sep 1 [cited 2025 Sep 5];29(3):160–8. Available from: https://doi.org/10.22146/ijbiotech.94293

Digambiro RA, Parwanto E, Ilona F, Chendrasari J, Lestari IW. D-dimer sebagai biomarker diagnostik tuberkulosis paru pada efusi pleura. Cermin Dunia Kedokteran [Internet]. 2025 [cited 2025 Aug 8];52(2):78–83. Available from: https://www.cdkjournal.com

Yorike D, Kurniawan MR, Syafaat M. Analysis of D-Dimer Level and PT–APTT on Heparin Use in COVID-19 Patients. Indones J Med Lab Sci Technol [Internet]. 2022 Apr 28 [cited 2025 Jul 30];4(1):91–8. Available from: https://doi.org/10.33086/ijmlst.v4i1.2487

Freedman RA, Caswell-Jin JL, Hassett M, Somerfield MR, Giordano SH. Optimal adjuvant chemotherapy and targeted therapy for early breast cancer—CDK4/6 inhibitors. J Clin Oncol [Internet]. 2024 Jan [cited 2025 Sep 11];42(18):2233–5. Available from: https://doi.org/10.1200/JCO.24.00886

Varikasuvu SR, Varshney S, Dutt N, Munikumar M, Asfahan S, Kulkarni PP, et al. D-dimer, disease severity, and deaths in COVID-19: systematic review. Sci Rep [Internet]. 2021 [cited 2025 Jul 15];11:14062. Available from: https://doi.org/10.1038/s41598-021-01462-5

Ozen M, Yilmaz A, Cakmak V, Beyoglu R, Oskay A, Seyit M, et al. D-dimer as a biomarker for COVID-19 severity. Am J Emerg Med [Internet]. 2021 Jan [cited 2025 Sep 6];40:55–59. Available from: https://doi.org/10.1016/j.ajem.2020.12.023

Lu Y, Zhang LY, Zhang QH, Zhang YJ, Chen DB, Lou JJ, et al. Association of D-dimer with clinicopathological features of breast cancer. PLoS One [Internet]. 2019 Sep 1 [cited 2025 Jul 24];14(9):e0221374. Available from: https://doi.org/10.1371/journal.pone.0221374

Hermansyah D, Firsty NN, Nasution RB, Andra CA, Lubis AC. Plasma D-dimer measurement to assist grading of breast cancer. Open Access Maced J Med Sci [Internet]. 2022 Feb 16 [cited 2025 Aug 29];10(B):565–9. Available from: https://doi.org/10.3889/oamjms.2022.8490

Alkhoder L, Salamoon M, Saifo M, Alwassouf S. D-dimer as a predictive marker of chemotherapy response in metastatic breast cancer. Biomark Insights [Internet]. 2024 [cited 2025 Sep 13];19:1–8. Available from: https://doi.org/10.1177/11772719241290704

Dybowska M, Dybowski D, Szturmowicz M, Jóźwik A, Lewandowska K, Sobiecka M, et al. D-dimer variability perioperatively predicts breast cancer relapse. Cancer Control [Internet]. 2023 Jan 1 [cited 2025 Aug 3];30:1–9. Available from: https://doi.org/10.1177/10732748231204713

Sreedevi S, Gowtham Shankar A, Vijayalakshmi C, Barath M. Role of plasma D-dimer levels in breast cancer. Int J Acad Med Pharm [Internet]. 2025 [cited 2025 Jul 22];7(2):36–41. Available from: https://www.academicmed.org/index.php/ijamp/article/view/3197

Wang Y, Liang X, Wang S, Wang Y, Qin L, Chen D, et al. Risk factors for elevated D-dimer after breast cancer surgery. Front Oncol [Internet]. 2022 Jul 19 [cited 2025 Aug 18];12:772726. Available from: https://doi.org/10.3389/fonc.2022.772726

Ghadhban BR. Plasma D-Dimer Levels Correlated with Advanced Breast Carcinoma in Female Patients: A Prospective Study at Baghdad Teaching Hospital. Acta Med Iran [Internet]. 2019 Mar [cited 2025 Jul 11];57(3):176–81. Available from: https://acta.tums.ac.ir/index.php/acta/article/view/8898

Siddiqui NA, Malik M, Wijeratne Fernando R, Sreekantan Nair A, Illango J, Gor R, et al. D-dimer in cancer screening and prognosis. Cureus [Internet]. 2021 May 17 [cited 2025 Sep 7];13(5):e15064. Available from: https://doi.org/10.7759/cureus.15064

Halugodu AS, Sharma VM. Correlation of plasma D-dimer with breast carcinoma. Int Surg J [Internet]. 2021 Nov 26 [cited 2025 Aug 26];8(12):3622–7. Available from: https://doi.org/10.18203/2349-2902.isj20214755

Gill SS, Gupta A, Trikha A, Adapa K, Kaur T, Gupta R, et al. AI-digital triaging for breast cancer screening. Eur J Cancer [Internet]. 2024 Mar [cited 2025 Jul 20];200:113797. Available from: https://doi.org/10.1016/j.ejca.2024.113797

Gochhait S, Sahoo S, Chhabra G, Mukhopahay A, Sharma S. Role of D-dimer in operable breast cancer with nodal metastasis. Oncol J India [Internet]. 2020 Apr[cited 2025 Aug 14];4(2):39–44. Available from: https://doi.org/10.4103/oji.oji_16_20

Novelyn S, Simanjuntak TSB. Incidence and grading of breast cancer at Tarakan Hospital Jakarta. Asian J Res Infect Dis [Internet]. 2025 Apr 17 [cited 2025 Sep 9];16(5):1–8. Available from: https://doi.org/10.9734/ajrid/2025/v16i5441